Across TCGA pan-cancer cohorts, HSD17B11 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HSD17B11 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher HSD17B11 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated HSD17B11 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where HSD17B11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	II,III,IV	0.940	0.700	.007	29	view →
LUAD	OS	Quartile	All	0.902	1.000	.030	12	view →
PDAC	OS	Tertile	All	0.669	0.454	.011	8	view →
LSCC	OS	Tertile	II,III,IV	0.622	0.945	.018	7	view →
UCEC	DFS	Median	All	0.936	1.000	.023	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: HSD17B11 tumor-vs-normal RNA expression · all HSD17B11 data types